Depomed confirms receipt of unsolicited proposal from Horizon Pharma
Depomed confirmed it has received an unsolicited, highly conditional, non-binding proposal from Horizon Pharma to acquire all of the outstanding shares of Depomed in an all-stock transaction valued at $29.25 per share. July 07, 2015